Corpus overview


MeSH Disease

HGNC Genes


age categories (4237)

Transmission (3651)

gender (1909)

fomite (1442)

contact tracing (1365)

    displaying 19161 - 19170 records in total 19597
    records per page

    The Effects of "Fangcang, Huoshenshan, and Leishenshan" Makeshift Hospitals and Temperature on the Mortality of COVID-19 MESHD

    Authors: Yuwen Cai; Tianlun Huang Sr.; Xin Liu Sr.; Gaosi Xu Sr.

    doi:10.1101/2020.02.26.20028472 Date: 2020-02-29 Source: medRxiv

    Background In December 2019, a novel coronavirus disease MESHD ( COVID-19 MESHD) broke out in Wuhan, China, however, the factors affecting the mortality remain unclear. Methods Thirty-two days of data that were shared by China National Health Commission and China Weather Net were collected using standard forms. The difference in the mortality of confirmed and severe cases before and after the use of Fangcang, Huoshenshan, and Leishenshan makeshift hospitals (MSHs) was tested using Mann-Whitney U test. We also studied whether air temperature ( AT MESHD) could affect the above outcomes of COVID-19 MESHD cases by performing Spearman analysis. Results The mortality of confirmed cases TRANS was significantly decreased both in Wuhan (U = 1, P < 0.001) and Hubei (U = 0, P < 0.001), while in non-Hubei regions, as a contrast, the mortality of confirmed cases TRANS remained unchanged (U = 40, P = 0.139). However, another eight days later, changes in the mortality in non-Hubei regions also became significant (U = 73, P = 0.039). Mortality of confirmed cases TRANS was found to be significantly correlated with temperature both in Wuhan (r = -0.441, P = 0.012) and Hubei (r = -0.440, P = 0.012). Conclusions Our findings indicated that both the use of MSHs and the rise of AT MESHD were beneficial to the survival of COVID-19 MESHD cases.

    Prediction of the Epidemic of COVID-19 MESHD Based on Quarantined Surveillance in China

    Authors: Rui Li; Wenliang Lu; Xifei Yang; Peihua Feng; Ozarina Muqimova; Xiaoping Chen; Gang Wei Sr.

    doi:10.1101/2020.02.27.20027169 Date: 2020-02-29 Source: medRxiv

    Background and Objective: To predict the epidemic of COVID-19 MESHD based on quarantined surveillance from real world in China by modified SEIR model different from the previous simply mathematical model. Design and Methods: We forecasted the epidemic of COVID-19 MESHD based on current clinical and epidemiological data and built a modified SEIR model to consider both the infectivity during incubation period TRANS and the influence on the epidemic from strict quarantined measures. Results: The peak time of the curve for the infected newly diagnosed as COVID-19 MESHD should substantially present on Feb.5,2020(in non-Hubei areas) and Feb.19,2020(in Hubei. It is estimated that the peak of the curve of the cumulative confirmed cases TRANS will appear in non-Hubei areas on Mar.3,2020 and in Hubei province on Mar.10,2020,and the total number of the patients diagnosed as COVID-19 MESHD is 18,000 in non-Hubei areas and 78,000-96,000 in Hubei.The Chinese COVID-19 MESHD epidemic can be completely controlled in May,2020. Conclusions: COVID-19 MESHD is only a local outbreak in Hubei Province,China.It can be probably avoided the pandemic of global SARS-CoV-2 cases rise with the great efforts by Chinese government and its people.

    A simple ecological model captures the transmission TRANS pattern of the coronavirus COVID-19 MESHD outbreak in China

    Authors: Feng Zhang; Jinmei Zhang; Menglan Cao; Cang Hui

    doi:10.1101/2020.02.27.20028928 Date: 2020-02-29 Source: medRxiv

    The rapid spread of the 2019 novel coronavirus ( COVID-19 MESHD), initially reported in the city of Wuhan in China, and quickly transmitted to the entire nation and beyond, has become an international public health emergency. Estimating the final number of infection cases and the turning point (time with the fastest spreading rate) is crucial to assessing and improving the national and international control measures currently being applied. In this paper we develop a simple model based on infectious growth with a time-varying infection rate, and estimate the final number of infections and the turning point using data updated daily from 3 February 2020, when China escalated its initial public health measures, to 10 February. Our model provides an extremely good fit to the existing data and therefore a reasonable estimate of the time-varying infection rate that has largely captured the transmission TRANS pattern of this epidemic outbreak. Our estimation suggests that (i) the final number of infections in China could reach 78,000 with an upper 95% confidence limit of 88,880; (ii) the turning point of the fastest spread was on the 4th or the 5th of February; and (iii) the projected period for the end of the outbreak (i.e., when 95% of the final predicted number of infection is reached) will be the 24th of February, with an upper 95% confidence limit on the 19th of March. This suggests that the current control measures in China are excellent, and more than sufficient to contain the spread of this highly infectious novel coronavirus, and that the application of such measures could be considered internationally for the global control of this outbreak.

    Sex differences in clinical findings among patients with coronavirus disease 2019 MESHD ( COVID-19 MESHD) and severe condition

    Authors: Jing Li; Yinghua Zhang; Fang Wang; Bing Liu; Hui Li; Guodong Tang; Zhigang Chang; Aihua Liu; Chunyi Fu; Jing Gao; Jing Li

    doi:10.1101/2020.02.27.20027524 Date: 2020-02-29 Source: medRxiv

    Objective: To compare the sex differences in the clinical findings among patients with severe coronavirus disease 2019 MESHD ( COVID-19 MESHD). Methods: We retrospectively collected data of 47 patients diagnosed as severe type of COVID-19 MESHD from February 8 to 22, 2020, including demographics, illness history, physical examination, laboratory test, management, and compared differences between men and women. Results: Of the 47 patients, 28 (59.6%) were men. The median age TRANS was 62 years, and 30 (63.8%) had comorbidities. The initial symptoms were mainly fever (34 [72.3%]), cough HP (36 [76.6%]), myalgia MESHD (5 [10.6%]) and fatigue HP fatigue MESHD (7 [14.9%]). Procalcitonin level was higher in men than in women (0.08 vs. 0.04ng/ml, p=0.002). N-terminal-pro brain natriuretic peptide increased in 16 (57.1%) men and 5 (26.3%) women (p=0.037). Five men (17.9%) had detected positive influenza A antibody SERO, but no women. During 2-week admission, 5 (17.9%) men and 1 (5.3%) woman were reclassified into the critical type due to deterioration. Mortality was 3.6% in men and 0 in women respectively. Four (21.1%) women and one man (3.6%) recovered and discharged from hospital. Conclusion: Sex differences may exist in COVID-19 MESHD patients of severe type. Men are likely to have more complicated clinical condition and worse in-hospital outcomes as compared to women.

    Evolution of CT Findings in Patients with COVID-19 MESHD Pneumonia

    Authors: Ting Liang; Carol C.Wu; Zhe liu; Chao Jin; Huifang Zhao; Yan Wang; Zekun Wang; Fen Li; Jie Zhou; Shubo Cai; Yukun Liang; Heping Zhou; Xibin Wang; Zhuanqin Ren; Jian Yang

    doi:10.21203/ Date: 2020-02-29 Source: ResearchSquare

    Objectives To delineate the evolution of CT findings in patients with mild COVID-19 MESHD pneumonia MESHD outside of Wuhan.Methods CT images and medical records of 88 patients with confirmed mild COVID-19 MESHD pneumonia MESHD outside of Wuhan, a baseline and at least one follow-up CT were retrospectively reviewed. CT features including lobar distribution and presence of ground glass opacities (GGO), consolidation, and linear opacities, were analyzed on per patient basis during each of five time intervals spanning the three weeks after disease onset. Total severity scores were calculated.Results 85.2 % of patients had travel TRANS history to Wuhan or known contact with infected individuals. The most common symptoms were fever MESHD (84.1%) and cough (56.8%). The baseline CT was obtained on average 5 days from symptom onset TRANS. Four patients (4.5%) had negative initial CT. Significant differences were found among the time intervals in the proportion of pulmonary lesions MESHD that are 1) pure GGO, 2) mixed attenuation, 3) mixed attenuation with linear opacities, 4) consolidation with linear opacities, and 5) pure consolidation. The majority of patients had involvement of ≥ 3 lobes. Bilateral involvement was more prevalent than unilateral involvement. The proportions of patients observed to have pure GGO or GGO and consolidation decreased over time while proportion of patients with GGO and linear opacities increased. Total severity score showed an increasing trend in the first two weeks. Conclusions While bilateral GGO are predominant features, CT findings changed during different time intervals in the three weeks after symptom onset TRANS in patients with COVID-19 MESHD.

    Therapeutic effects of dipyridamole on COVID-19 MESHD patients with coagulation dysfunction MESHD

    Authors: Xiaoyan Liu; Zhe Li; Shuai Liu; Zhanghua Chen; Zhiyao Zhao; Yi-you Huang; Qingling Zhang; Jun Wang; Yinyi Shi; Yanhui Xu; Jing Sun; Huifang Xian; Rongli Fang; Fan Bai; Changxing Ou; Bei Xiong; Andrew M Lew; Jun Cui; Hui Huang; Jincun Zhao; Xuechuan Hong; Yuxia Zhang; Fulin Zhou; Hai-Bin Luo

    doi:10.1101/2020.02.27.20027557 Date: 2020-02-29 Source: medRxiv

    The human coronavirus HCoV-19 infection can cause acute respiratory distress syndrome MESHD ( ARDS MESHD), hypercoagulability MESHD, hypertension MESHD, extrapulmonary multiorgan dysfunction. Effective antiviral and anti-coagulation agents with safe clinical profiles are urgently needed to improve the overall prognosis. We screened an FDA approved drug library and found that an anticoagulant agent dipyridamole (DIP) suppressed HCoV-19 replication at an EC50 of 100 nM in vitro. It also elicited potent type I interferon responses and ameliorated lung pathology in a viral pneumonia MESHD model. In analysis of twelve HCoV-19 infected patients with prophylactic anti-coagulation therapy, we found that DIP supplementation was associated with significantly increased platelet and lymphocyte counts and decreased D-dimer levels in comparison to control patients. Two weeks after initiation of DIP treatment, 3 of the 6 severe cases (60%) and all 4 of the mild cases (100%) were discharged from the hospital. One critically ill patient with extremely high levels of D-dimer and lymphopenia HP lymphopenia MESHD at the time of receiving DIP passed away. All other patients were in clinical remission. In summary, HCoV-19 infected patients could potentially benefit from DIP adjunctive therapy by reducing viral replication, suppressing hypercoagulability MESHD and enhancing immune recovery. Larger scale clinical trials of DIP are needed to validate these therapeutic effects.

    Clinical characteristics of 36 non-survivors with COVID-19 MESHD in Wuhan, China

    Authors: Ying Huang; Rui Yang; Ying Xu; Ping Gong

    doi:10.1101/2020.02.27.20029009 Date: 2020-02-29 Source: medRxiv

    Background Although the outbreak of Coronavirus disease 2019 MESHD ( COVID-19 MESHD) has caused over 2200 deaths in China, there was no study about death yet. We aimed to describe the clinical characteristics of non-survivors with COVID-19 MESHD. Methods For this retrospective, single-center study, we included 36 non-survivors with COVID-19 MESHD in the Fifth Hospital of Wuhan. Cases were confirmed TRANS by real-time RT-PCR between Jan 21 and Feb 10, 2020 according to the recommended protocol. The epidemiological, demographic, clinical, laboratory, radiological and treatment data were collected and analyzed. Outcomes were followed up until Feb 14, 2020. This study was approved by the ethics commissions of the Fifth Hospital of Wuhan, with a waiver of informed consent due to a public health outbreak investigation. Results We included 36 patients who died from COVID-19 MESHD. The mean age TRANS of the patients was 69.22 years (SD 9.64, range 50-90). 25(69.44%) patients were males TRANS, and 11 (30.56%) female TRANS. 26 (72.22%) patients had chronic diseases MESHD, mainly including hypertension MESHD, cardiovascular disease MESHD and diabetes MESHD. Patients had common clinical symptoms of fever MESHD (34 [94.44%] patients), cough (28 [77.78%] patients), shortness of breath MESHD (21 [58.33%] patients), and fatigue MESHD (17 [47.22%] patient). Chest computed tomographic scans showed that 31 (96.88%) patients had bilateral pneumonia MESHD. Lymphopenia HP Lymphopenia MESHD occurred in 24 patients (70.59%), decreased albumin (30.18, [SD, 4.76]) in 25 patients (80.65%), elevated D-dimer (8.64 [IQR, 2.39-20]) in 27 patients (100%), and elevated lactate dehydrogenase (502.5 U/L [IQR, 410-629]) in 26 patients (100%). Nearly all of the patients have elevated CRP (106.3 mg/L [IQR, 60.83-225.3]), PCT (0.61 ng/ml [IQR, 0.16-2.10]) and IL-6 HGNC (100.6 pg/ml [IQR, 51.51-919.5]). Most patients received antiviral therapy and antibiotic therapy, and more than half of patients received glucocorticoid therapy (25 [69.44%]). All the patients had acute respiratory distress syndrome MESHD ( ARDS MESHD). The median time from onset to ARDS MESHD was 11 days. One (2.78%) patient presented with acute renal injury MESHD. The median time from onset to death MESHD was 17 days. Interpretation Lots of patients died from COVID-19 MESHD till now. The median survival time of these non-survivors from onset to death was about 2 weeks. Most patients were older males TRANS with comorbidities. They finally progressed to ARDS MESHD. The median time from onset to ARDS MESHD was 11 days. Gradually decreased lymphocytes and increased inflammation MESHD biomarkers were common, and need to be monitored in the routine treatment.

    Potential Therapeutic Agents for COVID-19 MESHD Based on the Analysis of Protease and RNA Polymerase Docking

    Authors: Yu-Chuan Chang; Yi-An Tung; Ko-Han Lee; Ting-Fu Chen; Yu-Chun Hsiao; Hung-Ching Chang; Tsung-Ting Hsieh; Chan-Hung Su; Su-Shia Wang; Jheng-Ying Yu; Shang-shung Shih; Yu-Hsiang Lin; Yin-Hung Lin; Yi-Chin Ethan Tu; Chun-Hua Hsu; Hsueh-Fen Juan; Chun-Wei Tung; Chien-Yu Chen

    id:10.20944/preprints202002.0242.v2 Date: 2020-02-29 Source:

    The outbreak of novel coronavirus ( COVID-19 MESHD) infections in 2019 is in dire need of finding potential therapeutic agents. In this study, we used molecular docking to repurpose HIV protease inhibitors and nucleoside analogues for COVID-19 MESHD, with evaluations based on docking scores calculated by AutoDock Vina and RosettaCommons. Our results suggest that Indinavir and Remdesivir possess the best docking scores, and comparison of the docking sites of the two drugs reveal a near perfect dock in the overlapping region of the protein pockets. After further investigation of the functional regions inferred from the proteins of SARS coronavirus MESHD, we discovered that Indinavir does not dock on any active sites of the protease, which may give rise to concern in regards to the efficacy of Indinavir. On the other hand, the docking site of Remdesivir is not compatible with any known functional regions, including template binding motifs, polymerization motifs and nucleoside triphosphate (NTP) binding motifs. However, when we tested the active form (CHEMBL2016761) of Remdesivir, the docking site revealed a perfect dock in the overlapping region of the NTP binding motif. This result suggests that Remdesivir could be a potential therapeutic agent. Clinical trials still must be done in order to confirm the curative effect of these drugs.

    Hypokalemia MESHD and Clinical Implications in Patients with Coronavirus Disease 2019 MESHD ( COVID-19 MESHD)

    Authors: dong chen Jr.; Xiaokuni Li; qifa song Sr.; Chenchan Hu Jr.; Feifei Su; Jianyi Dai

    doi:10.1101/2020.02.27.20028530 Date: 2020-02-29 Source: medRxiv

    BACKGROUND: SARS-CoV-2 has caused a series of COVID-19 MESHD globally. SARS-CoV-2 binds angiotensin I converting enzyme 2 HGNC ( ACE2 HGNC) of renin-angiotensin system (RAS) and causes prevalent hypokalemia MESHD METHODS: The patients with COVID-19 MESHD were classified into severe hypokalemia MESHD, hypokalemia MESHD, and normokalemia group. The study aimed to determine the relationship between hypokalemia MESHD and clinical features, the underlying causes and clinical implications of hypokalemia HP hypokalemia MESHD. RESULTS: By Feb 15, 2020, 175 patients with COVID-19 MESHD (92 women and 83 men; median age TRANS, 46 [IQR, 34-54] years) were admitted to hospital in Wenzhou, China, consisting 39 severe hypokalemia MESHD-, 69 hypokalemia MESHD-, and 67 normokalemia patients. Gastrointestinal symptoms were not associated with hypokalemia MESHD among 108 hypokalemia MESHD patients (P>0.05). Body temperature, CK, CK-MB, LDH, and CRP HGNC were significantly associated with the severity of hypokalemia MESHD (P<0.01). 93% of severe and critically ill MESHD patients had hypokalemia MESHD which was most common among elevated CK, CK-MB, LDH, and CRP HGNC. Urine K+ loss was the primary cause of hypokalemia MESHD. severe hypokalemia HP hypokalemia MESHD patients was given 3 g/day, adding up to an average of 34 (SD=4) g potassium during hospital stay. The exciting finding was that patients responded well to K+ supplements when they were inclined to recovery. CONCLUSIONS: Hypokalemia MESHD is prevailing in patients with COVID-19 MESHD. The correction of hypokalemia MESHD is challenging because of continuous renal K+ loss resulting from the degradation of ACE2 HGNC. The end of urine K+ loss indicates a good prognosis and may be a reliable, in-time, and sensitive biomarker directly reflecting the end of adverse effect on RAS system.

    Highland of COVID-19 MESHD outside Hubei: epidemic characteristics, control and projections of Wenzhou, China

    Authors: Liangde Xu; Jian Yuan; Yaru Zhang; Guosi Zhang; Fan Lu; Jianzhong Su; Jia Qu

    doi:10.1101/2020.02.25.20024398 Date: 2020-02-29 Source: medRxiv

    In late December 2019, Chinese authorities reported a cluster of pneumonia MESHD cases of unknown aetiology in Wuhan, China. Wenzhou, as a southeast coastal city with the most cases outside Hubei Province, its policy control and epidemic projections have certain references for national and worldwide epidemic prevention and control. The maximum number of illness onset in Wenzhou appeared on January 26 (38 cases). Since January 27, the incidence per day in Wenzhou has continued to decline is likely to be due to isolation of people return to Wenzhou, implementation of region quarantine and suspension of public transportation system. Under the current control efforts, we estimate that the daily incidence by March 3-9, 2020 will drop to 0 in Wenzhou using SEIR model. The total number of affected people is 538.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.